PL3092003T3 - Nowe przeciwciało przeciw netrynie-1 - Google Patents
Nowe przeciwciało przeciw netrynie-1Info
- Publication number
- PL3092003T3 PL3092003T3 PL15700118T PL15700118T PL3092003T3 PL 3092003 T3 PL3092003 T3 PL 3092003T3 PL 15700118 T PL15700118 T PL 15700118T PL 15700118 T PL15700118 T PL 15700118T PL 3092003 T3 PL3092003 T3 PL 3092003T3
- Authority
- PL
- Poland
- Prior art keywords
- netrine
- antibody against
- new antibody
- new
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305034.2A EP2893939A1 (en) | 2014-01-10 | 2014-01-10 | Anti-netrin-1 antibody |
| PCT/EP2015/050306 WO2015104360A1 (en) | 2014-01-10 | 2015-01-09 | Novel anti-netrin-1 antibody |
| EP15700118.1A EP3092003B1 (en) | 2014-01-10 | 2015-01-09 | Novel anti-netrin-1 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3092003T3 true PL3092003T3 (pl) | 2020-05-18 |
Family
ID=49958401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15700118T PL3092003T3 (pl) | 2014-01-10 | 2015-01-09 | Nowe przeciwciało przeciw netrynie-1 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10494427B2 (pl) |
| EP (2) | EP2893939A1 (pl) |
| JP (1) | JP6586095B2 (pl) |
| KR (1) | KR102360967B1 (pl) |
| CN (1) | CN105979966B (pl) |
| AR (1) | AR099068A1 (pl) |
| AU (1) | AU2015205575B2 (pl) |
| BR (1) | BR112016015811B1 (pl) |
| CA (1) | CA2936308C (pl) |
| CL (1) | CL2016001753A1 (pl) |
| DK (1) | DK3092003T3 (pl) |
| EA (1) | EA034676B1 (pl) |
| ES (1) | ES2770620T3 (pl) |
| HR (1) | HRP20192313T1 (pl) |
| HU (1) | HUE048088T2 (pl) |
| IL (1) | IL246603B (pl) |
| LT (1) | LT3092003T (pl) |
| MX (1) | MX373326B (pl) |
| NZ (1) | NZ721975A (pl) |
| PH (1) | PH12016501339A1 (pl) |
| PL (1) | PL3092003T3 (pl) |
| PT (1) | PT3092003T (pl) |
| RS (1) | RS59818B1 (pl) |
| SG (1) | SG11201605562VA (pl) |
| SI (1) | SI3092003T1 (pl) |
| TW (1) | TWI699211B (pl) |
| WO (1) | WO2015104360A1 (pl) |
| ZA (1) | ZA201604640B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2893939A1 (en) * | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
| AR106543A1 (es) | 2015-11-02 | 2018-01-24 | Netris Pharma | Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético |
| EP3565837B1 (en) * | 2017-01-05 | 2024-04-10 | Netris Pharma | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
| EP4037712A4 (en) | 2019-10-04 | 2023-11-01 | Albert Einstein College of Medicine | KIR3DL3 IS AN IMMUNE SYSTEM INHIBITANT RECEPTOR AND USES THEREOF |
| MX2024001308A (es) * | 2021-07-27 | 2024-05-23 | Netris Pharma | Deteccion de netrina-1, prueba complementaria y terapia basada en radiaciones. |
| EP4245772A1 (en) | 2022-03-18 | 2023-09-20 | Netris Pharma | Anti-netrin-1 antibody to treat liver inflammation |
| EP4249509A1 (en) | 2022-03-22 | 2023-09-27 | Netris Pharma | Anti-netrin-1 antibody against arthritis-associated pain |
| CA3246346A1 (en) | 2022-03-29 | 2023-10-05 | Netris Pharma | NEW MCL-1 INHIBITOR AND COMBINATION OF MCL-1 AND A BH3 MIMETIC, SUCH AS A BCL-2 INHIBITOR |
| WO2024180085A1 (en) | 2023-02-27 | 2024-09-06 | Netris Pharma | Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains |
| CN119306826B (zh) * | 2023-07-11 | 2025-06-20 | 东莞市朋志生物科技有限公司 | 抗白介素-6抗体、检测白介素-6的试剂和试剂盒 |
| AU2024330301A1 (en) * | 2023-09-01 | 2026-03-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Anti-ly6 antibodies and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU2001293870A1 (en) | 2000-10-16 | 2002-04-29 | Bayer Aktiengesellschaft | Regulation of human netrin binding membrane receptor unc5h-1 |
| US20060025335A1 (en) | 2004-01-30 | 2006-02-02 | Kinane Thomas B | Netrin compositions and methods of using the same |
| JP2008506703A (ja) * | 2004-07-14 | 2008-03-06 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | ネトリン関連化合物および用途 |
| EP2322206A3 (fr) | 2004-11-22 | 2013-06-05 | Centre National de la Recherche Scientifique | Nétrine 1 mutée, ses fragments et leur utilisation comme médicaments |
| FR2878165A1 (fr) * | 2004-11-22 | 2006-05-26 | Centre Nat Rech Scient | Nouvelles utilisations des netrines |
| US20060153840A1 (en) | 2005-01-12 | 2006-07-13 | Anne Eichmann | Methods for preventing or treating a condition or a disease associated with angiogenesis |
| ES2601352T3 (es) | 2006-02-28 | 2017-02-14 | Centre National De La Recherche Scientifique (Cnrs) | Cribado para compuestos anti-cáncer usando actividad de netrina-1 |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2009141440A1 (en) | 2008-05-21 | 2009-11-26 | Centre National De La Recherche Scientifique (Cnrs) | Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma |
| JP5147062B2 (ja) | 2008-07-17 | 2013-02-20 | Ｎｅｃトーキン株式会社 | 巻線部品 |
| AR074369A1 (es) | 2008-11-20 | 2011-01-12 | Genentech Inc | Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso |
| EP2208738A1 (en) | 2009-01-09 | 2010-07-21 | Centre National pour la Recherche Scientifique (CNRS) | Method for the selection of endothelial cells death inducers via netrin-1 and its applications |
| WO2010090834A2 (en) * | 2009-01-20 | 2010-08-12 | The Penn State Research Foundation | Netrin-1 as a biomarker of injury and disease |
| EP2609430A1 (en) | 2010-08-26 | 2013-07-03 | F.Hoffmann-La Roche Ag | Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc |
| EP2708241A1 (en) * | 2012-09-12 | 2014-03-19 | Netris Pharma | Recombinant Fc-fusion protein of the two Immunoglobulin domains of UNC5 |
| EP2708231A1 (en) * | 2012-09-12 | 2014-03-19 | Netris Pharma | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug |
| DK3024484T3 (en) * | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| EP2893939A1 (en) * | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
-
2014
- 2014-01-10 EP EP14305034.2A patent/EP2893939A1/en not_active Withdrawn
-
2015
- 2015-01-09 HU HUE15700118A patent/HUE048088T2/hu unknown
- 2015-01-09 LT LTEP15700118.1T patent/LT3092003T/lt unknown
- 2015-01-09 TW TW104100790A patent/TWI699211B/zh active
- 2015-01-09 DK DK15700118.1T patent/DK3092003T3/da active
- 2015-01-09 RS RS20200058A patent/RS59818B1/sr unknown
- 2015-01-09 WO PCT/EP2015/050306 patent/WO2015104360A1/en not_active Ceased
- 2015-01-09 CA CA2936308A patent/CA2936308C/en active Active
- 2015-01-09 KR KR1020167018645A patent/KR102360967B1/ko active Active
- 2015-01-09 HR HRP20192313TT patent/HRP20192313T1/hr unknown
- 2015-01-09 EA EA201691212A patent/EA034676B1/ru not_active IP Right Cessation
- 2015-01-09 BR BR112016015811-3A patent/BR112016015811B1/pt active IP Right Grant
- 2015-01-09 SI SI201531074T patent/SI3092003T1/sl unknown
- 2015-01-09 NZ NZ721975A patent/NZ721975A/en unknown
- 2015-01-09 CN CN201580007753.8A patent/CN105979966B/zh active Active
- 2015-01-09 AR ARP150100062A patent/AR099068A1/es active IP Right Grant
- 2015-01-09 AU AU2015205575A patent/AU2015205575B2/en active Active
- 2015-01-09 ES ES15700118T patent/ES2770620T3/es active Active
- 2015-01-09 US US15/110,612 patent/US10494427B2/en active Active
- 2015-01-09 JP JP2016545904A patent/JP6586095B2/ja active Active
- 2015-01-09 SG SG11201605562VA patent/SG11201605562VA/en unknown
- 2015-01-09 MX MX2016009029A patent/MX373326B/es active IP Right Grant
- 2015-01-09 EP EP15700118.1A patent/EP3092003B1/en active Active
- 2015-01-09 PL PL15700118T patent/PL3092003T3/pl unknown
- 2015-01-09 PT PT157001181T patent/PT3092003T/pt unknown
-
2016
- 2016-07-04 IL IL246603A patent/IL246603B/en active IP Right Grant
- 2016-07-05 PH PH12016501339A patent/PH12016501339A1/en unknown
- 2016-07-07 ZA ZA2016/04640A patent/ZA201604640B/en unknown
- 2016-07-08 CL CL2016001753A patent/CL2016001753A1/es unknown
-
2019
- 2019-10-18 US US16/657,200 patent/US11648309B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| PL3556777T3 (pl) | Konstrukty przeciwciał wieloswoistych | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| DK3183051T3 (da) | Væske-til-luftmembranenergivekslere | |
| IL291164A (en) | Anti-nme antibody | |
| DK3134402T3 (da) | 4-amino-imidazoquinolinforbindelser | |
| DK3211743T3 (da) | Ø-til-netværk-omskiftningsfremgangsmåde | |
| DK3006072T3 (da) | Karadgang | |
| IL256099A (en) | Antibody | |
| DK3222714T3 (da) | Phytasemutanter | |
| DK3110442T3 (da) | Modificerede meningokok-fhbp-polypeptider | |
| EP4011484C0 (en) | CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS | |
| DK4242916T3 (da) | Forstøver | |
| LT3092003T (lt) | Naujas anti-netrino-1 antikūnas | |
| DK3183340T3 (da) | Termolabile exonukleaser | |
| DE112015001664A5 (de) | Betätigungsaktuator | |
| DK3154703T3 (da) | Fuldkappe-snekkecentrifuge | |
| IL257368A (en) | Antibody | |
| DE112015005041A5 (de) | Gargerätevorrichtung | |
| EP3160502B1 (en) | BI-SPECIFIC ANTIBODIES ANTI-IL4-IL13 | |
| LT3628731T (lt) | Naujas antipresepsino antikūnas | |
| DK3110439T3 (da) | Pcsk9-vacciner | |
| DE102014000623A8 (de) | Halbhohlnietelement | |
| HUE054148T2 (hu) | Anti-ORAI1 antitest | |
| LT3126391T (lt) | Hpa-1a antikūnai |